An observational study in Cardiopulmonary Bypass, Coronary Artery Bypass and Heart Valve Diseases, sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Heart Valve Diseases with a site in Italy — 21 open to participants now, 26 under way, none of them phase 3. Heart Valve Diseases · Italy.
Among the 48 studies in Heart Valve Diseases with a site in Italy, this one is the 14th largest by planned enrollment of the 28 observational ones that give a count, is one of 2 that started in 2026, is one of 28 observational ones, reaches primary completion later than 11 of the 25 other live ones, and was the 48th registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →21 of the 48 studies in Heart Valve Diseases with a site in Italy are open now. Recruiting first, the newest first:
Maria Cecilia Hospital · Sites in Italy
Ages 18+
Edwards Lifesciences · Sites in Italy, Germany, Greece and 3 more countries
Abbott Medical Devices · Sites in Italy, United States, Denmark and 7 more countries
Montreal Heart Institute · Sites in Italy, United States, Canada and 2 more countries
Ages 18+
Montefiore Medical Center · Sites in Italy, United States, Canada and 5 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 213 is below the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Median enrollment 73 across the 20 interventional studies, 207 across the 28 observational. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 48 have an industry lead sponsor. The 10 most frequent:
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital has 1 study filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Valve Diseases with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07125469Maria Cecilia HospitalComparing Measurements of the Aortic Valve Taken During Surgery With Those Obtained Before Surgery Using Computed Tomography Scans, in Patients Undergoing Surgical Aortic Valve Replacement | 2026-12 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT07330869Città di Lecce Hospital, GVM Care & ResearchWarfarin Effects on Male Fertility After Cardiac Surgery | 2027-02 |
| NCT06902922Francesco MaisanoImpact of Severe Tricuspid Regurgitation Correction on Gut Microbiota and Gastrointestinal Function | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 48 studies in Heart Valve Diseases with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn whether global longitudinal strain (GLS), measured by echocardiography, can predict difficulty separating from cardiopulmonary bypass (CPB) in adults undergoing elective cardiac surgery.
The main questions it aims to answer are:
Participants will:
Background and Rationale
Difficult separation from cardiopulmonary bypass (CPB) is a serious intraoperative complication associated with increased perioperative morbidity and mortality. Myocardial contractility is the key determinant of successful CPB separation, and perioperative echocardiography is an established method for evaluating ventricular function. Conventionally, left ventricular ejection fraction (LVEF) measured by Simpson's biplane method is used to assess myocardial performance. However, LVEF has notable limitations, including high inter-operator variability, preload/afterload dependence, and poor sensitivity in detecting early myocardial dysfunction.
Global longitudinal strain (GLS), measured by two-dimensional speckle-tracking echocardiography, has emerged as a sensitive, reproducible, and geometry-independent parameter of myocardial function. GLS can detect subtle ventricular dysfunction earlier than conventional LVEF and has demonstrated prognostic value in a variety of clinical settings. Despite this, its use in the perioperative cardiac surgery population remains limited, partly due to uncertainty about the optimal timing of assessment. Anesthesia induction, CPB, and myocardial protection strategies may alter myocardial performance, and therefore both absolute GLS values and dynamic perioperative changes may carry prognostic significance.
Study Objectives
The primary objective of this prospective, multicenter, observational study is to evaluate the predictive value of GLS measurements for difficult separation from CPB. Specifically, the study will assess whether GLS measured by preoperative transthoracic echocardiography (TTE) can independently predict the need for multiple inotropic/vasoactive agents during CPB weaning.
Secondary objectives include exploring the associations between GLS parameters and postoperative outcomes such as intensive care unit (ICU) and hospital length of stay, postoperative changes in cardiac biomarkers, and all-cause 30-day mortality.
Methods
Eligible patients are adults (>18 years) scheduled for elective cardiac surgery requiring CPB, including isolated valve replacement or repair, coronary artery bypass grafting (CABG), combined procedures, and ascending aortic/arch surgery. Patients undergoing emergency or redo surgery, those with contraindications to TEE, or in critical preoperative states (mechanical circulatory support, inotrope dependence, atrial fibrillation, or mechanical ventilation) are excluded.
Echocardiographic assessments are performed at standardized time points: preoperative TTE (T1), intraoperative TEE after induction (T2, if performed), before CPB initiation (T3), immediately after CPB weaning (T4), and following sternal closure (T5). Intraoperative TEE is not mandated by the protocol but may be performed according to institutional practice or operator discretion. GLS analysis follows American Society of Echocardiography (ASE) guidelines, averaging strain from 18 myocardial segments.
Anesthetic and surgical protocols follow institutional standards, with cardioplegia delivered via Buckberg's or del Nido solutions. Clinical, intraoperative, and postoperative data-including operative times, need for pharmacologic support, and recovery variables-are collected systematically by trained staff.
Outcomes
Significance
This study addresses a clinically important knowledge gap by evaluating the GLS as a novel predictor of intraoperative difficulty and adverse outcomes in cardiac surgery. If validated, GLS assessment could enhance perioperative risk stratification, guide intraoperative decision-making, and ultimately improve patient outcomes.
Adult patients scheduled for elective cardiac surgery requiring cardiopulmonary bypass at participating tertiary cardiac surgery centers. The study recruits participants from routine surgical practice in academic and high-volume referral hospitals, where both valve and coronary artery procedures are performed. Consecutive eligible patients who provide informed consent are enrolled prospectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligible surgical procedures include:
Exclusion Criteria
Critical preoperative conditions, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Easy separation from CPB was defined as no pharmacologic support or use of a single agent (either vasoactive or inotropic).
Diagnostic Test: Myocardial strain imaging
Difficult CPB separation can be defined as the need of at least 2 inotropes or vasopressors to successfully accomplish the separation from CPB.
Diagnostic Test: Myocardial strain imaging
Two-dimensional strain analysis was performed using frame-by-frame tracking of unique patterns of bright and dark pixels in grayscale (B-mode) sector images to assess myocardial deformation. The frame rate was maintained between 40 and 90 Hz. The myocardium in each image was divided into six myocardial segments, which were individually assessed for tracking quality. GLS was calculated as the average strain value of 18 myocardial segments obtained from the three echocardiographic views. Patients were included in the final analysis if at least 15 out of 18 segments were considered acceptable for strain measurement by the investigator.
To evaluate the predictive value of GLS measurements for difficult separation from cardiopulmonary bypass.
Separating from CPB was categorized as easy and difficult separation from CPB. Easy separation from CPB was defined as no pharmacologic support or use of a single agent (either vasoactive or inotropic). Difficult CPB separation can be defined as the need of at least 2 inotropes or vasopressors to successfully accomplish the separation from CPB
Time frame: perioperative
To assess the associations between strain imaging and ICU/hospital length of stay, postoperative trajectories of cardiac biomarkers, and all-cause mortality.
Time frame: Post operative 30 days
Plan to share: No
Start is estimated for Feb 2026; primary completion for Jul 2026, 5 months later.
Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 5 months is below that.
Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital